BBVA USA’s Gilead Sciences GILD Stock Holding History

BBVA USA’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$2.47M	Buy	35,407 +576	+2%	+$40.5K	0.15%	148
2021 Q2	$2.4M	Buy	+34,831	New	+$2.33M	0.13%	150

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BBVA USA's GILD Position: Q3 2021 in Review

BBVA USA increased its Gilead Sciences (GILD) stake by 1.7% in Q3 2021, buying an estimated $40.5K and bringing the position to 35,407 shares worth $2.47M. The position accounts for 0.15% of the portfolio, ranked #148.

BBVA USA first reported a position in GILD in Q2 2021 and has held it in 2 quarters since. 1,563 funds tracked by Wall St. Rank hold GILD as of Q3 2021.

BBVA USA held 35,407 shares of Gilead Sciences worth $2.47M as of Q3 2021.
BBVA USA bought 576 Gilead Sciences shares in Q3 2021, an estimated $40.5K.
Gilead Sciences made up 0.15% of BBVA USA's portfolio in Q3 2021, its #148 holding.
BBVA USA first reported a position in Gilead Sciences in Q2 2021 and has held it in 2 quarters since.
1,563 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2021.

Based on BBVA USA's 13F filing for Q3 2021, filed 4 Nov 2021.